Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches
October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.
You may also be interested in...
Y-mAbs Faces Delay In Pediatric Neuroblastoma With Refuse-To-File Letter
Omburtamab, for CNS metastases resulting from neuroblastoma, needs more clinical and CMC data for its rolling BLA to be reviewed. The company says timelines for lead candidate naxitamab should not be affected.
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma
The Suzhou-based drug developer brings in new cash as US venture deals take a holiday. Also, France's Genfit may go public in the US, Taiwan Liposome launches its IPO, and Bioblast's strategic review ends in a reverse merger.